ATE216997T1 - Zyklische gmp-spezifische phosphodiesteraseinhibitoren - Google Patents

Zyklische gmp-spezifische phosphodiesteraseinhibitoren

Info

Publication number
ATE216997T1
ATE216997T1 AT96923986T AT96923986T ATE216997T1 AT E216997 T1 ATE216997 T1 AT E216997T1 AT 96923986 T AT96923986 T AT 96923986T AT 96923986 T AT96923986 T AT 96923986T AT E216997 T1 ATE216997 T1 AT E216997T1
Authority
AT
Austria
Prior art keywords
phosphodiesterase inhibitors
cyclic gmp
specific phosphodiesterase
specific
gmp
Prior art date
Application number
AT96923986T
Other languages
English (en)
Inventor
Alain Daugan
Francoise Gellibert
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Application granted granted Critical
Publication of ATE216997T1 publication Critical patent/ATE216997T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT96923986T 1995-07-14 1996-07-11 Zyklische gmp-spezifische phosphodiesteraseinhibitoren ATE216997T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9514465.5A GB9514465D0 (en) 1995-07-14 1995-07-14 Chemical compounds
PCT/EP1996/003025 WO1997003985A1 (en) 1995-07-14 1996-07-11 Cyclic gmp-specific phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
ATE216997T1 true ATE216997T1 (de) 2002-05-15

Family

ID=10777696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96923986T ATE216997T1 (de) 1995-07-14 1996-07-11 Zyklische gmp-spezifische phosphodiesteraseinhibitoren

Country Status (24)

Country Link
US (1) US5981527A (de)
EP (1) EP0846118B1 (de)
JP (1) JP4150818B2 (de)
CN (1) CN1069318C (de)
AR (1) AR003455A1 (de)
AT (1) ATE216997T1 (de)
AU (1) AU702324B2 (de)
BR (1) BR9609780A (de)
CA (1) CA2226761A1 (de)
CO (1) CO4700455A1 (de)
CZ (1) CZ3298A3 (de)
DE (1) DE69621026T2 (de)
ES (1) ES2176471T3 (de)
GB (1) GB9514465D0 (de)
HR (1) HRP960321B1 (de)
HU (1) HUP9900006A3 (de)
IL (1) IL122923A0 (de)
MX (1) MX9800411A (de)
NO (1) NO980154L (de)
PL (1) PL324527A1 (de)
SK (1) SK3898A3 (de)
WO (1) WO1997003985A1 (de)
YU (1) YU42296A (de)
ZA (1) ZA965934B (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
CA2294480C (en) 1997-06-23 2008-05-20 Queen's University At Kingston Microdose therapy of female sexual dysfunction by no, co, and their donors
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
CA2365782A1 (en) * 1999-04-30 2000-11-09 William E. Pullman Treatment of female arousal disorder
NO20002097L (no) 1999-04-30 2001-10-26 Lilly Icos Llc Fremstillingsgjenstander
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
NZ516616A (en) * 1999-08-03 2003-07-25 Lilly Icos Llc Beta-carboline pharmaceutical compositions
US20040152106A1 (en) * 1999-10-07 2004-08-05 Robertson Harold A. Gene necessary for striatal function, uses thereof, and compounds for modulating same
JP2003510349A (ja) * 1999-10-07 2003-03-18 ノヴァ−ニューロン インコーポレーテッド 線条体機能に必要な遺伝子、その使用、およびそれを調節するための化合物
EP1222190A1 (de) 1999-10-11 2002-07-17 Pfizer Limited 2-(2-substituted-5-heterocyclylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-one als phosphodiesterasehemmer
IL139457A0 (en) 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US20040254153A1 (en) * 1999-11-08 2004-12-16 Pfizer Inc Compounds for the treatment of female sexual dysfunction
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
CA2407031A1 (en) 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
CA2412596C (en) 2000-06-23 2007-07-31 Lilly Icos Llc Cyclic gmp-specific phosphodiesterase inhibitors
WO2002010166A1 (en) * 2000-08-02 2002-02-07 Lilly Icos Llc Fused heterocyclic derivatives as phosphodiesterase inhibitors
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ATE552013T1 (de) * 2000-09-06 2012-04-15 Mitsubishi Tanabe Pharma Corp Zubereitungen zur oralen anwendung
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
MXPA03002909A (es) 2000-10-02 2003-09-10 Lilly Icos Llc Compuestos quimicos.
EP1325007B1 (de) * 2000-10-02 2005-06-15 Lilly Icos LLC Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
CA2427573C (en) 2000-11-06 2008-10-07 Lilly Icos Llc Indole derivatives as pde5-inhibitors
US6960587B2 (en) 2000-11-08 2005-11-01 Lilly Icos Llc Condensed pyrazindione derivatives as PDE inhibitors
EP1366760B1 (de) * 2001-02-15 2010-06-30 Mitsubishi Tanabe Pharma Corporation Tabletten, die in der mundhöhle schnell zerfallen
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
EP1401449B1 (de) * 2001-06-05 2007-04-25 Lilly Icos LLC Tetrazyklische verbindungen als pde5-inhibitoren
ES2269679T3 (es) * 2001-06-21 2007-04-01 Lilly Icos Llc Derivados de carbolina como inhibidores de pdev.
WO2003042216A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
ES2337887T3 (es) * 2001-12-20 2010-04-30 Merck Serono Sa Derivados de pirrolidina en calidad de moduladores de prostaglandina.
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
ES2318175T3 (es) * 2002-07-31 2009-05-01 Lilly Icos Llc Reaccion pictet-splenger modificada y productos preparados a partir de la misma.
US20070010450A1 (en) 2003-06-13 2007-01-11 Microbia, Inc., A Massachusetts Corporation Methods and compositions for the treatment of gastrointestinal disorders
WO2006049986A1 (en) * 2004-10-28 2006-05-11 Dr. Reddy's Laboratories Ltd. Polymorphic forms of tadalafil
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
EP2258359A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
ZA200804550B (en) 2005-11-09 2009-08-26 Combinatorx Inc Methods, compositions, and kits for the treatment of medical conditions
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (de) * 2006-09-08 2009-06-17 Braincells, Inc. Kombinationen mit einem 4-acylaminopyridin-derivat
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (de) 2012-01-10 2014-11-26 President and Fellows of Harvard College Betazellen-replikation für promoterverbindungen und verwendungsverfahren dafür
WO2014055801A1 (en) 2012-10-05 2014-04-10 Henkin Robert I Phosphodiesterase inhibitors for treating taste and smell disorders
CN104230960B (zh) * 2013-06-06 2017-02-15 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
EP3082428A4 (de) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5-inhibitorpulverformulierungen und zugehörige verfahren
CN104804016B (zh) * 2014-01-23 2017-06-20 山东轩竹医药科技有限公司 四并环类间变性淋巴瘤激酶抑制剂
US10598672B2 (en) 2014-02-18 2020-03-24 Cyrano Therapeutics, Inc. Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
JP6687550B2 (ja) 2014-06-23 2020-04-22 セルジーン コーポレイション 肝疾患又は肝機能異常を治療するためのアプレミラスト
EP3728266A1 (de) 2017-12-20 2020-10-28 Novartis AG Kondensierte tricyclische pyrazolo-dihydropyrazinyl-pyridonverbindungen als viruzide
EP3759075B1 (de) * 2018-02-28 2025-07-23 Ferro Therapeutics, Inc. Verbindungen mit ferroptosis-induzierender aktivität und verfahren zu deren verwendung
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
WO2021194893A1 (en) 2020-03-24 2021-09-30 Cyrano Therapeutics, Inc. Treatment of chemosensory dysfunction from a coronavirus infection
EP4684777A1 (de) 2024-07-24 2026-01-28 Adalvo Limited Pharmazeutische zusammensetzung mit fixer dosis mit (2s)-2-[(4,6-dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropansäure und (6r,12ar)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,12,12a-hexahydropyrido[3,4-b!indol-1,4-dion

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GR79603B (de) * 1982-07-24 1984-10-31 Pfizer
IT1217190B (it) * 1988-04-22 1990-03-14 Recordati Chem Pharm Composti utili per il trattamento e diagnosi di disfunzioni frettili
EP0357122A3 (de) * 1988-08-29 1991-10-23 Duphar International Research B.V Verwendung von Beta-Carbolinen und deren bio-isosterischen Benzofuran- und Benzothiophenanalogen zur Herstellung eines Arzneimittels mit cytostatischer Wirkung
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
DK0459666T3 (da) * 1990-05-31 1994-12-05 Pfizer Lægemidler mod impotens
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds

Also Published As

Publication number Publication date
PL324527A1 (en) 1998-06-08
JP4150818B2 (ja) 2008-09-17
CN1069318C (zh) 2001-08-08
CA2226761A1 (en) 1997-02-06
EP0846118A1 (de) 1998-06-10
BR9609780A (pt) 1999-03-09
NO980154L (no) 1998-03-10
WO1997003985A1 (en) 1997-02-06
CN1195349A (zh) 1998-10-07
HUP9900006A2 (hu) 1999-04-28
ZA965934B (en) 1997-02-03
HRP960321B1 (en) 2003-06-30
CZ3298A3 (cs) 1998-06-17
DE69621026D1 (de) 2002-06-06
NO980154D0 (no) 1998-01-13
GB9514465D0 (en) 1995-09-13
CO4700455A1 (es) 1998-12-29
ES2176471T3 (es) 2002-12-01
HUP9900006A3 (en) 1999-11-29
US5981527A (en) 1999-11-09
IL122923A0 (en) 1998-08-16
JPH11509535A (ja) 1999-08-24
MX9800411A (es) 1998-04-30
SK3898A3 (en) 1998-11-04
HRP960321A2 (en) 1998-08-31
AU6419296A (en) 1997-02-18
AR003455A1 (es) 1998-08-05
YU42296A (sh) 1998-12-23
DE69621026T2 (de) 2002-08-22
EP0846118B1 (de) 2002-05-02
AU702324B2 (en) 1999-02-18

Similar Documents

Publication Publication Date Title
DE69621026D1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
ATE189461T1 (de) Cyclische adhäsionsinhibitoren
FI973492L (fi) NO-syntaasin estäjät
PT858464E (pt) Inibidores de trombina
PT863916E (pt) Tripeptidos de polifluoroalquil triptofano inibidores de trombina
FI2165U1 (fi) Skyddande trosor med aoteranvaendbar sugdel
BR9610514A (pt) Inibidores cicloantihelmínticos
FI1943U1 (fi) Bomsystem till skogmaskin
KR970703937A (ko) 금속단백질 분해효소 억제제(Metallproteinase inhibitors)
FI953861A0 (fi) Tillaeggsanordning till saekerhetslaos i doerrars innerkanter
FI2002U1 (fi) Haollare till spoestaell
FI2187U1 (fi) Hoerndetalj till plaottlaoda
FI2196U1 (fi) Snoestyrningsblad till snoeslunga
FI1863U1 (fi) Vaeggkonstruktion till timmerhus
FI951168A0 (fi) Kraftoeverfoeringsanordning till rotationskolvmotor
FI954177A0 (fi) Tillaeggsanordning till lyfttruck
FI950830A0 (fi) Skaer till valskross
FI956132A0 (fi) Kopplingskrok till skjutarm
FI950851A0 (fi) Mekanism till kraftoeverfoeringsanordning
FI954672A0 (fi) Utbytbar kupolslitdel till en kupolventil
FIU950360U0 (fi) Mellanlaeggsflaens till axeltaetning
FI950280A0 (fi) Smaeltsaekring till en brandsaekerhetsanordning
FI950473A0 (fi) Vaeggkonstruktion till timmerhus
FI955199A0 (fi) Anordning till lyftbom
FI955029A0 (fi) Inbrottsskydd till brevlucka